Skin barrier repairing and anti-aging effects evaluation of a comprehensive topical regimen incorporating niacinamide, Pro-Xylane, and panthenol after PicoWay laser: a randomized controlled study Authors: Huijuan Liu, Baiyu Li, Xiaofeng He, Rui Li, Runlin Mi, Chunyu Zhao, Caixia Ye, Wenna Wang, Hequn Wang, Zailing Zhu, Xiaoyin Zhou, Kungchi Hsu, Andrew Steel, Jie Qiu, Yi Yi, Yueqing Niu, Claire Huguet, Wei Xiong, Valentine Beguin, Delphine Kerob, Yijie Zheng Published: 2026 ABSTRACT AbstractPro-Xylane is a potent anti-aging ingredient; however, there is limited knowledge regarding whether a comprehensive post-procedure regimen incorporating a combination of Pro-Xylane, niacinamide, and panthenol alongside other active agents can deliver synergistic benefits for both skin barrier repair and anti-aging. This study assesses the effectiveness of the REGENMEDIC cream (anti-aging cream) and REGENMEDIC serum (anti-aging serum) in promoting skin barrier recovery and enhancing anti-aging effects following PicoWay laser treatment. A 112-day randomized controlled trial was conducted with 88 Chinese females, who were divided into two groups: the test group, using REGENMEDIC cream and Serum following PicoWay laser treatment, and the control group, using standard care regimen consisting of a standard cream. Skin barrier-repairing effects were assessed during the initial 14 days following a single use of REGENMEDIC cream, while skin elasticity, firmness, wrinkles and skin tone were evaluated over the 112-day study period after the combined use of REGENMEDIC cream and Serum. The test group exhibited lower transepidermal water loss (TEWL) and higher hydration after 14 days compared to the control group, along with a more significant reduction in skin redness. After 112-day use of REGENMEDIC cream and serum, test group showed increased skin elasticity and firmness, reduced wrinkles, and an overall improvement in skin tone and texture. Dermatologists reported excellent tolerability, with minimal adverse events. Initial application of the REGENMEDIC cream facilitated rapid skin barrier repair, while the subsequent sequential regimen incorporating the serum yielded significant long-term anti-aging benefits following PicoWay laser treatment. This study demonstrates that targeting multiple physiological pathways—specifically hydration, barrier integrity, and cellular senescence—provides a robust therapeutic option for amplifying the anti-aging outcomes of aesthetic procedures.Keywords: PicoWay, Skin barrier repair, Anti-aging, REGENMEDIC cream, REGENMEDIC serum Introduction Skin aging is a complex biological process influenced by both intrinsic and extrinsic factors [1]. Intrinsic aging, also known as chronological aging, is genetically determined and occurs naturally over time, leading to a gradual decline in skin elasticity, hydration, and cellular regeneration. Extrinsic aging, on the other hand, is influenced by environmental factors, primarily UV radiation, pollution, and lifestyle factors like smoking and diet [2]. At the intrinsic level, aging results from genetically programmed physiological changes, including a decrease in the proliferative capacity of dermal fibroblasts, leading to reduced collagen and elastin production [3]. The visible manifestations of these changes include fine lines, wrinkles, and a decline in skin elasticity and hydration. Externally, factors such as UV radiation and pollution exacerbate these signs by inducing oxidative stress and inflammatory responses, further compromising skin barrier and accelerating aging processes [3–5]. The role of the skin barrier is crucial, as it regulates hydration through transepidermal water loss (TEWL) and protects against environmental insults. Damage to this barrier disrupts its protective function, leading to increased susceptibility to irritants, pathogens, and dehydration, all of which contribute to premature aging [6]. Therefore, skin barrier restoration and maintenance are essential, making it a central component of any anti-aging strategy. Advancements in dermatological treatments have led to the development and widespread use of laser technologies for skin rejuvenation [7]. The PicoWay system was prioritized for this study due to its predominantly photoacoustic mechanism, which contrasts with the photothermal action of traditional nanosecond lasers. By utilizing picosecond pulses to generate laser-induced optical breakdown (LIOB) in the dermis, this technology stimulates robust collagen remodeling while preserving the surrounding tissue from excessive thermal stress. This profile is particularly beneficial for Asian skin phototypes, as it significantly mitigates the risk of post-inflammatory hyperpigmentation while optimizing rejuvenation outcomes. This technology not only facilitates the breakdown of pigmentation but also promotes dermal remodeling by stimulating collagen production, which improves skin texture and elasticity. As a result, the mechanism of action allows for targeted treatment of skin concerns such as hyperpigmentation, fine lines, and wrinkles, with minimal damage to surrounding tissues. Moreover, patients benefit from improved skin appearance with reduced recovery time compared to traditional laser treatments [8]. However, the use of such laser treatments also has challenges. The primary issue following laser intervention is the temporary disruption of the skin’s barrier function, characterized by erythema, edema, and an increase in TEWL [9]. This compromise of the skin’s defense mechanisms can result in discomfort and prolong recovery if not properly managed [10]. Consequently, these challenges necessitate post-treatment strategies to mitigate discomfort and accelerate recovery, thereby enhancing the overall efficacy and outcomes of the laser procedures. In the absence of adequate post-procedural care, the compromised epidermis remains vulnerable to environmental insults, potentially undermining the clinical benefits of the laser intervention. Consequently, dermocosmetics formulated with bioactive ingredients have emerged as essential therapeutic adjuncts [11]. The integration of these targeted formulations not only accelerates immediate tissue recovery but also sustains long-term aesthetic outcomes by preserving dermal collagen and optimal hydration levels [12, 13]. Furthermore, this holistic approach to post-laser care ensures that the skin recovers more effectively while preserving the rejuvenating advantages offered by the laser treatment. Given the importance of comprehensive skin care post-laser treatment, this study aims to evaluate the efficacy of a new anti-aging cream (REGENMEDIC cream) and serum (REGENMEDIC serum) in enhancing skin barrier repair and anti-wrinkle effects post-PicoWay laser treatment. By integrating bioactive ingredients known to support skin repair, this regimen is expected to enhance the skin’s recovery process, restoring the skin barrier and promoting longer-lasting aesthetic improvements. Methodology Study design This single-center, open-label, evaluator-blinded study, conducted by SGS-CSTC Standards Technical Services (Shanghai) Co., Ltd., an independently operated testing and certification company (reference number: QDCPCH24000110, SGS ethics committee for clinical research No. 2024005), enrolled Chinese female participants aged 35–60 years who underwent PicoWay laser treatment. All laser procedures were performed using a standardized protocol with the PicoWay system (Candela, USA). Specifically, the 1064 nm wavelength was employed using the Resolve fractional handpiece, with a fluence of 0.7–1.1 J/cm2 and a spot size of 6 mm. The pulse duration was fixed at 450 ps for all participants to ensure treatment consistency and minimize confounding variables arising from varying energy delivery. The study spanned 112 days and included eight visits: baseline (Day0 [D0]) and on days 3 (D3), day 7 (D7), day 14 (D14), day 28 (D28), day 56 (D56), day 84 (D84), and day 112 (D112), to assess both short-term and long-term outcomes. The test group received PicoWay treatment followed by La Roche-Posay REGENMEDIC cream and La Roche-Posay REGENMEDIC serum, while the control group underwent the same laser treatment but applied a basic vehicle cream. This control formulation comprised fundamental emollients and humectants (e.g., glycerin and petrolatum) but was entirely devoid of the active anti-aging complex, specifically niacinamide, Pro-Xylane, and panthenol, thereby serving as an inert comparator to isolate the biological effects of the test ingredients. The exact quantitative concentrations (w/w) of the active ingredients—specifically niacinamide, Pro-Xylane, and panthenol—within the tested REGENMEDIC formulations are proprietary to the manufacturer and therefore cannot be publicly disclosed. Participant selection In this 112-day randomized controlled trial, 88 Chinese female participants were allocated in a 1:1 ratio to either the test group (REGENMEDIC cream plus serum with PicoWay laser) or the control group (standard care regimen). Randomization was conducted using a computer-generated block sequence (block size = 4) by an independent statistician with allocation concealment through sealed envelopes opened post baseline assessments and consent. All of them were healthy women aged 35–60, of Asian (Chinese) ethnicity, and met specific inclusion criteria for facial pigmentation, wrinkles, and skin conditions as outlined in the protocol. Inclusion criteria Participants were included if they had: 1) Facial pigmentation spots graded 2–6 based on the SkinAging Atlas, a validated clinical photographic scale specifically developed for evaluating signs of aging in Asian populations [14]; 2) Nasolabial fold wrinkles graded 3–6 on one randomly selected side utilizing the identical atlas; 3) Crow’s feet wrinkles graded 3–6 on one randomly selected side utilizing the identical atlas; 4) Obvious fine lines on facial cheeks, static fine lines in nasolabial and mouth areas, sagging in lower facial areas; 5) Rough, sagging, and lack of firmness in facial skin; 6) No cosmetic medical treatment in the past month; 7) Willingness to enroll after PicoWay treatment; 8) Agreement to sign a photo consent form; 9) No significant facial skin damage, scars, or hair problems; 10) Ability to comply well with the trial requirements and maintain a regular lifestyle during the study period. Exclusion criteria Participants were excluded if they were unwilling to sign informed consent or follow the study protocol; participated in another evaluation study; or used cosmetics or drugs on the day of evaluation. Additionally, exclusions included pregnancy, breastfeeding, active infections, or recent cosmetic treatments. Specific criteria also barred those with photosensitive skin conditions, psychological illnesses, or systemic diseases that could interfere with the evaluation. Those with excessively high treatment expectations, or histories of significant sun exposure or use of oral retinoid medications, were also excluded. Intervention Prior to the PicoWay treatment, comprehensive safety evaluations of all products were conducted, including toxicology assessments, human patch tests, and safety data collection. Participants committed to reporting any adverse reactions encountered during the trial. From Day 0 to Day 14, the test group applied La Roche-Posay REGENMEDIC cream twice daily, using 0.3 g in the morning and 0.6 g in the evening. Starting on Day 15 and continuing through Day 112, the test group also applied La Roche-Posay REGENMEDIC serum, using one dropper each morning and evening, in conjunction with the cream and physical sunscreen (SPF 15). It is important to note that this serum introduces additional active ingredients, specifically peptides and a gradual-release retinol derivative. In contrast, control group applied the standardized inert vehicle cream (containing the same base formulation as the test products but without bioactive agents) and physical sunscreen (SPF 15) throughout the 112-day study period, without an equivalent vehicle serum comparator. All participants were required to apply sunscreen every morning and use additional physical protection such as sun hats during outdoor activities to ensure consistent UV protection. Outcome of interest The primary endpoint of this study was the evaluation of skin barrier repair efficacy following PicoWay laser treatment, specifically defined as the change from baseline in transepidermal water loss (TEWL) and stratum corneum hydration levels during the initial 14-day post-procedure period. The key indicators assessed for skin barrier function included TEWL and hydration levels. Secondary endpoints focused on the long-term anti-aging and rejuvenation outcomes over the 112-day study duration. These included objective measurements of skin elasticity (R2, R5, R7) and firmness (F4), clinical grading of wrinkle reduction across multiple facial zones (forehead, under-eye, nasolabial folds, cheek fine lines, and crow’s feet), and assessments of skin tone evenness and radiance. In this study, the anti-aging effect is evaluated as a multi-dimensional construct rather than a single metric. While increases in epidermal and dermal thickness serve as critical structural indicators, the anti-aging outcome is fundamentally marked by the concurrent reduction in clinical wrinkle severity across multiple facial zones and the improvement of biomechanical skin properties, specifically gross elasticity (R2), net elasticity (R5), and biological recovery (R7). Outcome measures and data collection Throughout the 112-day study period, both objective and subjective measures were employed to evaluate the efficacy of the product at specified time points—Day 0, 3, 7, 14, 28, 56, 84, and 112. The objective evaluations included TEWL, assessed with a Tewameter to determine skin barrier integrity, and stratum corneum moisture content, measured using a Corneometer to gauge hydration levels. Skin elasticity and firmness parameters, specifically R2 (gross elasticity), R5 (net elasticity), R7 (biological elasticity), and F4 (firmness), were analyzed using a Cutometer. Concurrently, epidermal and dermal thickness and density were non-invasively quantified with the DermaLab® Combo equipped with a high-frequency (20 MHz) ultrasound probe. This technology allows for the visualization of skin layers and the measurement of acoustic density, which serves as a proxy for the concentration and organization of extracellular matrix components, such as collagen and glycosaminoglycans. Additionally, glossiness was evaluated with a Glossymeter, and pigmentation variations were measured with a Mexameter. Standardized facial photography was captured using the VISIA Complexion Analysis System under cross-polarized lighting to objectively quantify changes in erythema and redness area. Furthermore, high-definition multidirectional illumination imaging via the Antera 3D system was utilized to assess wrinkle severity and micro-relief topography. Specifically, this sophisticated imaging facilitated the precise quantification of skin smoothness (SEsm), roughness (SEr), and scaliness (SEsc), alongside the calculation of the standard deviation of hue (Hue-SD) as an indicator of global skin tone evenness. Furthermore, to minimize detection bias, independent dermatologists who were strictly blinded to the participants’ treatment allocations conducted clinical evaluations at baseline and subsequent intervals, using a severity scale from 0 to 9 to rate wrinkle severity, pigmentation, and overall skin health. This comprehensive approach ensured a thorough analysis of the product’s effects throughout the study. Timeline and follow-up assessments Before treatment, baseline evaluations were conducted for each participant, including high-definition imaging, moisture content evaluation, TEWL, skin elasticity, firmness, glossiness, and pigmentation assessments. These comprehensive assessments established a critical baseline for comparing the pre- and post-treatment effects of the products. Immediate repair efficacy, focusing on TEWL and moisture content, was assessed at short-term follow-up points on Day 3, 7, and 14 to evaluate the initial improvements in skin barrier function. Furthermore, long-term follow-up assessments were conducted on Day 28, 56, 84, and 112, focusing on the wrinkle-reducing efficacy of the treatment. These included measurements of wrinkle area, texture, and skin elasticity using advanced imaging techniques such as Antera 3D and VISIA, alongside other dermal assessments. Safety assessment Adverse events were closely monitored throughout the 112-days study. Participants maintained daily logs of any skin reactions or discomfort, which were reviewed by dermatologists during each visit. Routine skin assessments and detailed evaluations by dermatologists were conducted to identify and manage any adverse reactions. In the event of severe reactions, medical interventions were immediately available, and safety review meetings ensured continuous oversight. Upon study completion, a final safety assessment was conducted, with follow-up care provided as needed. A comprehensive final safety report was compiled based on the data collected during the trial. Statistical analysis The sample size was determined based on a power analysis using preliminary data from previous skin barrier studies. A total of 88 participants was calculated to provide 80% power at a 5% significance level (α = 0.05) to detect a statistically significant difference in transepidermal water loss (TEWL) between the two groups, accounting for an anticipated 15% dropout rate. Data were analyzed using SPSS 28.0. Each dataset underwent normality testing via the Shapiro–Wilk test to ascertain distribution characteristics. To account for the longitudinal nature of the trial and within-subject correlations over multiple visits, a two-way repeated measures analysis of variance (ANOVA) was employed to evaluate the effects of treatment group, time, and their interaction. Post-hoc comparisons at individual time points were conducted using the Bonferroni correction to adjust for multiple comparisons. Results are presented as mean ± standard deviation, complemented by 95% confidence intervals and effect sizes (partial eta squared) for primary endpoints to ensure methodological transparency and rigor. Statistical significance was set at p < 0.05. The results were summarized with high-resolution images from VISIA, DermaLab® Combo, and Antera 3D to visually document skin changes. Results Baseline characteristics of the participants A total of 88 female participants were enrolled in this study, with 46 randomly assigned to the test group and 42 to the control group. The participants in the test group had a mean age of 50.04 years (SD = 6.82), ranging from 37 to 60 years, while the control group had a mean age of 49.19 years (SD = 8.05), ranging from 35 to 59 years. All participants were categorized as having Fitzpatrick skin phototypes III or IV. Detailed demographic data are presented in Table 1. Table 1Baseline characteristics of participantsParameterTest groupControl groupP ValueNumber4642-Age range (y, Mean ± SD)37—60 (50.04 ± 6.82)35—59 (49.19 ± 8.05)NSPhototype (n, %)Ⅰ00-Ⅱ00-Ⅲ18 (39.1%)8 (19.0%)-Ⅳ28 (60.9%)34 (81.0%)-Skin type (n, %)Combination33 (71.7%)26 (61.9%)-Dry7 (15.2%)8 (19.0%)-Normal3 (6.5%)7 (16.7%)-Oily3 (6.5%)1 (2.4%)-NS not significant, SD standard deviation Baseline characteristics of participants NS not significant, SD standard deviation Skin barrier repair and soothing effects of the test cream The initial phase of the study evaluated the efficacy of the REGENMEDIC cream in promoting skin barrier repair during the first 14 days post-PicoWay treatment, specifically focusing on transepidermal water loss (TEWL) and stratum corneum hydration. When analyzing the absolute change from baseline, the test group exhibited a significantly greater reduction in TEWL during the initial 14 days compared to the control group (D3: −0.6 g/h/m2 vs. 0.54 g/h/m2, P < 0.05; D7: −1.76 g/h/m2 vs. 0.25 g/h/m2, P < 0.01; D14: −2.83 g/h/m2 vs. −0.40 g/h/m2, P < 0.001). Furthermore, this effect persisted throughout the test period. By D112, the test group achieved a TEWL reduction of 6.57 g/h/m2, compared to a reduction of 3.02 g/h/m2 in the control group, indicating enhanced skin barrier repair efficacy (Fig. 1A). Similarly, stratum corneum hydration levels in the test group showed significant improvement both on D14 and D112, compared to the control group (D14: 2.86 a.u. vs. −5.09 a.u.; D112: 14.30 a.u. vs. 4.68 a.u.), highlighting an enhanced moisturizing effect over the study duration (Fig. 1B). Measurements of TEWL, skin hydration level and skin redness over the course of the study. (A) Trans epidermal Water Loss (TEWL) values in the control and test groups from Day 3 to Day 112 (g/h/m.2). (B) Stratum corneum hydration levels in the control and test groups from Day 3 to Day 112. (C) Skin redness values measured on Days 3, 7, and 14 in the control and test groups. (D) Percentage of redness area observed on Days 3, 7, and 14. (E) Erythema Index (EI) recorded on Days 3, 7, and 14 in the control and test groups. (F) Visual assessments obtained via VISIA imaging on Day 0 (before and after the procedure), and Days 3, 7, and 14.* p < 0.05, ** p < 0.01 and *** p < 0.001 In terms of redness and erythema, the test group exhibited significantly greater reductions. The a* values, which indicate skin redness, showed marked decreases in the test group, with more reductions observed on D3, D7, and D14 compared to the control group, with a notable decrease of 3.67 in a* values for skin redness on D14 (P < 0.01). (Fig. 1C). Similarly, redness area (%) and the Erythema Index (EI) followed a comparable trend, demonstrating more pronounced improvements in the test group across all time points relative to the control group, with reductions of 7.34% and 38.12% on D14 (Fig. 1D, E). Furthermore, the visual assessments via VISIA imaging supported these findings, demonstrating a significantly reduction in redness in the test group (Fig. 1F). Skin structure improvements (skin thickness/density, skin elasticity and firmness) REGENMEDIC cream and serum demonstrated significant improvements in both epidermal and dermal structures following PicoWay laser treatment, as quantified by the Dermalab® Combo. Notably, increases in epidermal/dermal thickness and density were significantly greater in the test group compared to the control group (Fig. 2A-D). On Day 112, the test group exhibited an epidermal thickness of 36.45 μm, compared to 5.75 μm in the control group. Epidermal density was 14.21 in the test group, significantly higher than the control group’s 2.1. Similarly, dermal thickness measured 147.35 μm in the test group, exceeding the control group’s 24.71 μm. Dermal density also showed a substantial increase in the test group, at 11.79 versus 1.04 in the control group. These enhancements were consistent with visual data on the skin’s structural changes, as shown in Fig. 2E, suggesting that the skin barrier has become stronger and healthier. Furthermore, on Day 112, the test group exhibited a total skin elasticity of 0.188, elastic recovery ability of 0.217, and proportion of net skin elasticity of 0.283, while the control group showed values of 0.02, 0.01, and 0.03, respectively. Skin elasticity was notably higher in the test group compared to the control group, with a greater increase in R2 (total skin elasticity) and R7 (elastic recovery ability) values from D14 to D112, and a more significant increase in R5 (proportion of net skin elasticity) starting from D28 (Fig. 3A-C). Increase in epidermal and dermal density and thickness. (A) Epidermal thickness and (B) epidermal density expressed as absolute increases from baseline (Day 0, prior to laser intervention) in the control and test groups from Day 14 to Day 112. (C) Dermal thickness and (D) dermal density expressed as absolute increases from baseline in the control and test groups from Day 14 to Day 112. (E) Visual documentation of skin structural changes from Day 0 (before and after procedure) through Day 112. * p < 0.05, ** p < 0.01 and *** p < 0.001 indicate statistically significant differences between the test and control groups at the specified time points Improvement in skin elasticity and firmness. (A) R2 (total skin elasticity), (B) R5 (proportion of net skin elasticity), (C) R7 (elastic recovery ability) and (D) F4 (skin firmness) values in the control and test groups from Day 14 to Day 112. * p < 0.05, ** p < 0.01 and *** p < 0.001 Similarly, skin firmness in the test group progressively improved over time, as indicated by a decrease in F4 value from −0.24 on D14 to −0.81 on D112, indicating robust improvement in skin firmness. In contrast, the F4 value in the control group showed relatively minor changes, affirming the superior efficacy of REGENMEDIC cream and Serum in improving both skin firmness and tone (Fig. 3D). Anti-wrinkle effects Significant improvements in wrinkle reduction were observed following treatment with REGENMEDIC cream and Serum. The test group exhibited significant decreases in wrinkle area compared to the control group. These improvements persisted through Day 112, significantly reducing various types of wrinkles, including under-eye wrinkles (Day 112: Test −1.98 vs. Control −0.13, P < 0.01), forehead wrinkles (Day 112: Test −1.86 vs. Control −0.16, P < 0.001), nasolabial folds (Day 112: Test −2.31 vs. Control −0.34, P < 0.01), cheek fine lines (Day 112: Test −2.07 vs. Control −0.14, P < 0.001), and crow’s feet (Day 112: Test −1.56 vs. Control −0.07, P < 0.001), as shown in Fig. 4A–E. Additionally, the visual evidence of crow’s feet from the trial clearly depicts these advancements at multiple stages (Fig. 4F). Reduction of forehead wrinkles, nasolabial folds, fine lines on the cheeks, and crow’s feet. (A-E) Under-eye wrinkle area, forehead wrinkle area, nasolabial fold area, area of fine lines and crow’s feet area on the cheeks from Day 14 to Day 112 in control and test groups. (F) Visual evidence of crow’s feet progression during the trial from Day 14 to Day 112. * p < 0.05, ** p < 0.01 and *** p < 0.001 Skin tone and skin texture improvement Skin topography parameters, including skin smoothness (SEsm), roughness (SEr), and scaliness (SEsc), showed significant improvements among participants using REGENMEDIC cream and Serum post-PicoWay laser. Notably, decreases in SEsm and SEsc were observed from D7 to D112, alongside an obvious increase in SEr from D3 to D112, indicating a better skin texture. In contrast, the control group exhibited smaller changes, highlighting a less significant improvement in skin texture (Fig. 5A-C). Additionally, following PicoWay treatment, melanin levels significantly decreased during the initial 14 days of using REGENMEDIC cream, with a 13.96 reduction compared to baseline, while the control group only experienced a 4.13 decrease on D14 (Fig. 5D). Subsequently, from D14 through D112, the test group exhibited increased glossiness, as measured by the Glossymeter® GL200, indicating enhanced radiance (Fig. 5E). Moreover, significant enhancements in skin tone evenness were observed in the test group, unlike the more modest changes seen in the control group (Fig. 5F). Improvement in skin texture, skin tone, skin glossiness and evenness. (A-F) Skin smoothness (Sesm), skin roughness (Ser), skin scaliness (Sesc), melanin levels (MI), skin glossiness (G.U.) and skin tone evenness (Hue-SD) from Day 3 to Day 112 in the control and test groups. (G) Brown spot feature counts from Day 14 to Day 112 comparing test and control groups. * p < 0.05, ** p < 0.01 and *** p < 0.001 However, there is no obvious difference in brown spot counts from D14 to D112 between test group and control group (Fig. 5G). A possible explanation for the lack of further improvement in brown spot counts is that picosecond lasers specifically target existing pigmentation and are highly effective at reducing it. As a result, the use of cream and serum after picosecond laser treatment may not provide additional benefits in decreasing pigmentation. Collectively, these findings strongly demonstrate the effectiveness of REGENMEDIC cream and Serum in enhancing skin brightness and improving skin tone evenness. Safety assessments Following the PicoWay procedure, participants across both cohorts exhibited expected transient cutaneous responses, such as mild erythema, dryness, and desquamation, which constitute standard physiological sequelae of laser-induced photomechanical stress. Crucially, the application of the REGENMEDIC regimen did not exacerbate these anticipated downtime reactions; instead, it demonstrated excellent clinical tolerability with no product-related severe adverse events reported. Specifically, notable improvements were recorded in several parameters on D112: the changes in fever, burning sensation, and tightness were all reported as 0, indicating no progression or onset of these symptoms. Furthermore, the severity of peeling symptoms decreased from −0.39 to −0.59 on a predefined scale, suggesting a slight but favorable reduction. Additionally, the variations in erythema (redness), dryness, desquamation (scaling), and pruritus (itching) were relatively minimal, demonstrating stability in these skin conditions. These observations indicate that the test products are safely tolerated on compromised skin during the acute post-laser recovery phase. While the evaluated parameters primarily reflect the natural resolution of laser-induced downtime rather than a complete absence of cutaneous reactions, the lack of prolonged irritation supports the suitability of this regimen as a safe adjunctive care option. Discussion The integration of advanced cosmeceuticals following laser treatments, as demonstrated in this study assessing the efficacy of REGENMEDIC cream and Serum post-PicoWay laser treatment, represents a broader trend aimed at enhancing dermatological care and patient outcomes through targeted, post-procedure skincare. Our findings demonstrate a dual-phase benefit: the REGENMEDIC cream significantly accelerated acute barrier recovery within the first 14 days, while the subsequent addition of the serum into the daily regimen sustained and amplified the long-term anti-aging outcomes. This sequential protocol provided a robust framework for both immediate post-procedural repair and cumulative rejuvenation. These findings affirm the role of bioactive cosmeceuticals in supporting skin barrier repair and augmenting the long-term anti-aging effects of laser interventions. The REGENMEDIC cream alone was instrumental in accelerating recovery during the critical initial 14-day window, effectively mitigating laser-induced transepidermal water loss and erythema. The REGENMEDIC regimen features key components such as niacinamide, Pro-Xylane, and panthenol, renowned for their effectiveness in anti-aging skincare. The success of REGENMEDIC in combating aging can be attributed to a variety of mechanisms. One vital aspect is the synergistic impact of niacinamide and panthenol [15]. Niacinamide boosts skin metabolism and cell regeneration, accelerating the turnover of skin cells, while panthenol aids in skin absorption through hydration reactions, facilitating the intake of active ingredients. When combined, niacinamide and panthenol fortify the skin barrier, ultimately enhancing skin resilience. Additionally, Pro-Xylane stimulates glycosaminoglycan synthesis, promoting the production of hyaluronic acid and collagen for firmer skin. Previous studies have demonstrated that hyaluronic acid, which shares a similar structure to Pro-Xylane, exhibits significant synergistic effects with panthenol [16]. Therefore, it is reasonable to believe that when combined with panthenol, which provides deep hydration and supports skin elasticity and firmness, Pro-Xylane could help repair the compromised skin barrier, ultimately enhancing skin recovery and resilience. The clinical efficacy of the REGENMEDIC regimen is likely supported by the complementary mechanisms of its primary bioactive constituents. Niacinamide facilitates epidermal barrier restoration and improves skin radiance, whereas panthenol provides intensive humectant properties and accelerates cellular turnover [17]. Complementing these, Pro-Xylane functions as a structural scaffold by stimulating the synthesis of glycosaminoglycans and reinforcing the dermal–epidermal junction [18]. This multi-pathway integration effectively addresses post-laser thermal stress while providing sustained physiological rejuvenation, which likely contributes to the favorable long-term aesthetic outcomes observed in the test group. This study stands out as one of the few that has systematically assessed both short-term and long-term recovery outcomes following laser procedures, providing a comprehensive understanding of the benefits of such post-laser skincare regimens. Emerging research underscores the significance of utilizing specialized products to accelerate recovery and amplify the effects of laser treatments. A study by Boen, M et al. [19] reported that serums containing antioxidants and peptides significantly improved skin hydration and elasticity post-laser treatment, highlighting the potential of such formulations to mitigate oxidative stress and support skin regeneration. These findings underscore the rationale behind our study’s use of bioactive ingredients to improve skin barrier function and aesthetics post-laser [15]. When comparing our results to similar studies, we found a consistent pattern of enhanced recovery when topical agents were applied post-laser treatment [20]. A previous study assessing the impact of EGF on melanin index (MI) scores revealed a significant decrease in the EGF groups compared to controls one month post-laser surgery (SMD −1.57, 95% CI −2.83 to −0.31, p = 0.01) [20]. Similarly, recent studies focusing on picosecond lasers also highlighted the need for adjunctive skincare to prolong the beneficial effects of laser treatments, particularly in preventing post-inflammatory hyperpigmentation and maintaining collagen integrity [21, 22]. Another prior study examined the effects of laser-assisted hyaluronic acid (HA) on skin texture and firmness, showing that HA usage resulted in greater improvements in facial skin remodeling, skin texture (mean score of 2.60 vs. 2.45), and skin firmness (mean score of 2.55 vs. 2.40) at the three-month evaluation point [21, 22]. Notably, our study stands out by offering a more comprehensive evaluation than previous research. By examining not only hydration, redness, and melanin index, but also key anti-aging parameters such as wrinkle area and skin elasticity, our research provide a more holistic understanding of the post-laser recovery process. Additionally, advancements in fractional and picosecond lasers have not only enhanced the safety and efficacy of skin rejuvenation procedures but also provided precise control over energy delivery [7]. This minimizes damage to surrounding tissues and promotes rapid recovery, aligning closely with the goals of study focusing on rapid skin barrier repair following PicoWay treatments. The REGENMEDIC regimen’s ability to improve skin structure and elasticity was especially noteworthy. Compared to the control group, which received standard post-care, the test group experienced significantly greater improvements in both skin firmness and wrinkle reduction. The substantial structural improvements observed in the test group likely stem from a coordinated acceleration of dermal remodeling. While picosecond lasers induce localized photo-acoustic stress that triggers a wound-healing response and de novo collagen synthesis, the addition of Pro-Xylane provides the biochemical substrate necessary for this process by stimulating the production of glycosaminoglycans and stabilizing the dermal–epidermal junction. Furthermore, niacinamide and panthenol optimize the metabolic environment for fibroblasts by mitigating post-procedure inflammation and maintaining optimal hydration, which accounts for the pronounced gains in dermal thickness and density reported in our findings. Although the experimental design precludes the isolation of the specific contributions of the serum from those of the cream after Day 15, the overall clinical trajectory suggests that the integrated use of these two formulations provides a complementary effect, where the initial barrier stabilization by the cream creates an optimal physiological environment for the subsequent anti-aging benefits of the serum. This study contributes to a growing body of evidence supporting the use of targeted dermocosmetics in post-laser care regimens and opens avenues for further research. Future research should focus on optimizing these formulations to accommodate the specific inflammatory responses and recovery kinetics of diverse skin phototypes. Furthermore, the potential of such targeted dermocosmetics to maintain long-term cutaneous health and delay the recurrence of photoaging signs warrants extensive longitudinal investigation. Ultimately, our findings advocate for a paradigm shift in aesthetic dermatology. They emphasize meticulous post-laser care strategies that guarantee both immediate epidermal repair and enduring dermal rejuvenation. Despite its strengths, this study has several limitations. First, it was conducted exclusively on Chinese female participants with Fitzpatrick skin types III and IV. While the fundamental biological mechanisms of epidermal barrier repair and collagen neogenesis are highly conserved across different human populations, the clinical magnitude of these responses may vary. For instance, lighter skin types, such as Fitzpatrick I and II, might exhibit different erythema resolution kinetics. Conversely, darker skin types, including Fitzpatrick V and VI, present a distinct risk profile for post-inflammatory hyperpigmentation following laser interventions. Furthermore, structural differences in male skin, such as increased dermal thickness and distinct sebum production rates, necessitate caution when extrapolating these findings across genders. Future multi-center trials incorporating diverse ethnic cohorts and male participants are therefore essential to validate the universal applicability of this post-laser regimen. Secondly, although the 112-day follow-up allowed assessment of both short- and long-term effects, a longer follow-up is needed to confirm the durability of these benefits. Finally, although an evaluator-blinded design was implemented to minimize detection bias during clinical evaluations, the open-label nature of the product application by participants could still present a residual source of performance bias. Additionally, the study was conducted in a controlled clinical setting, suggesting that real-world adherence and outcomes may differ. A further limitation pertains to the proprietary nature of the tested commercial cosmetic formulations. Because the precise quantitative concentrations (w/w) of the key active ingredients cannot be disclosed, direct reproducibility of the topical intervention and precise dose-dependent comparisons with existing literature are inherently constrained. A further significant methodological limitation is the lack of a vehicle-matched control serum during the long-term maintenance phase (Days 15–112). Furthermore, the REGENMEDIC serum utilized in the test group contains additional potent anti-aging actives, notably peptides and a gradual-release retinol derivative, which serve as co-interventions and potential confounders. Consequently, the long-term anti-aging benefits observed cannot be exclusively attributed to the niacinamide, Pro-Xylane, and panthenol combination alone, but should rather be interpreted as the outcome of the overall sequential treatment regimen. Acknowledgements The authors extend their sincere gratitude to the participants of this study, whose commitment and cooperation made this research possible. Special thanks are extended to the staff at SGS-CSTC Standards Technical Services (Shanghai) Co., Ltd., for their support in conducting the trial and to the technical team for their assistance with the advanced imaging and skin assessment technologies. The authors also appreciate the invaluable input and feedback from our peer reviewers, which greatly enhanced the quality of this manuscript. Author contribution This study was collaboratively developed and executed. Huijuan Liu and Yijie Zheng conceptualized the study and led its design and protocol execution. Rui Li and Baiyu Li took a lead role in data collection, data analysis and manuscript preparation. All authors were involved in the interpretation of data. Delphine Kerob, Wei Xiong provided critical revisions to deepen the scholarly content. All authors reviewed and approved the final manuscript and are accountable for all aspects of the work. Funding This study was funded by L’Oreal Dermatological Beauty China, La Roche Posay. Data availability The study reports analysis of clinical research data collected from 88 Chinese female participants who completed a 112-day randomized controlled trial following PicoWay laser treatment. Data include instrumental skin-physiology measurements (TEWL, hydration, elasticity, firmness, erythema/melanin index, glossiness, radiance) and high-definition 3D imaging quantification outputs (Antera 3D, VISIA 3D). All raw and processed participant-level data supporting statistical conclusions are securely stored by the independent clinical-ethics-approved testing center SGS-CSTC Standards Technical Services (Shanghai) Co., Ltd. Due to privacy and consent agreements, de-identified aggregated data may be shared upon reasonable academic request to the corresponding author, without compromising participant confidentiality. Statistical analyses were performed using SPSS 28.0, with significance thresholds set at p < 0.05. Declarations Ethics approval and consent to participate This study was approved by the SGS Ethics Committee for Clinical Research, SGS-CSTC Standards Technical Services (Shanghai) Co., Ltd. (reference number: QDCPCH24000110; ethics approval No. 2024005). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent to participate was obtained from all participants before enrollment. All participants were fully informed about the study procedures, their rights, confidentiality protection, and their right to withdraw from the study at any time. Consent for publication Written consent for the publication of anonymized study-related information and images was obtained from all participants. No personally identifiable information is presented in this manuscript. Clinical trial registration This study was designed as an efficacy evaluation of topically applied dermocosmetic formulations following a standard aesthetic procedure, rather than an interventional clinical trial investigating a novel pharmacological agent or medical device. Consequently, formal registration in a public clinical trial database was not mandated by local regulatory guidelines for cosmetic evaluation studies. Nevertheless, the study protocol was conducted under the oversight and prior approval of an independent ethics committee to ensure participant safety and scientific rigor. Competing interests L’Oréal Dermatological Beauty China, La Roche Posay. Footnotes Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The study reports analysis of clinical research data collected from 88 Chinese female participants who completed a 112-day randomized controlled trial following PicoWay laser treatment. Data include instrumental skin-physiology measurements (TEWL, hydration, elasticity, firmness, erythema/melanin index, glossiness, radiance) and high-definition 3D imaging quantification outputs (Antera 3D, VISIA 3D). All raw and processed participant-level data supporting statistical conclusions are securely stored by the independent clinical-ethics-approved testing center SGS-CSTC Standards Technical Services (Shanghai) Co., Ltd. Due to privacy and consent agreements, de-identified aggregated data may be shared upon reasonable academic request to the corresponding author, without compromising participant confidentiality. Statistical analyses were performed using SPSS 28.0, with significance thresholds set at p < 0.05.